Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus

Diabetic Medicine

Volumn 19, Issue 11, 2002, Pages 944-948

  Tan, K C B ^b   Tso, A W K ^b   Tam, S C F ^a   Pang, R W C ^a   Lam, K S L ^b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Free fatty acids; Lipase inhibitor; Triglyceride; Triglyceride rich lipoprotein remnants; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL DERIVATIVE; FATTY ACID; GLUCOSE; LIPOPROTEIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLORIMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEFECATION; DIABETIC OBESITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DYSPEPSIA; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOLOGICAL PROCEDURES; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SEPARATION TECHNIQUE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-OBESITY AGENTS; CHOLESTEROL; CROSS-OVER STUDIES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPERLIPIDEMIAS; LACTONES; LIPASE; LIPOPROTEINS; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 0036432963     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2002.00823.x     Document Type: Article

References (36)

1. Nero N, Syvanne M, Taskinen MR. Postprandial lipid metabolism in diabetes. Atherosclerosis 1998; 141: S53-55.
2. Chen YD, Swami S, Skowronski R, Coulston A, Reaven GM. Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 76: 172-177.
3. Tan KCB, Cooper MB, Ling KL, Griffin BA, Freeman DJ, Packard CJ et al. Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: The involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis 1995; 113: 273-287.
4. Watanabe N, Taniguchi T, Taketoh H, Kitagawa Y, Namura H, Yoneda N et al. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type II diabetes patients. Diabetes Care 1999; 22: 152-156.
5. Hirany S, O'Byrne D, Devaraj S, Jialal I. Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease. Clin Chem 2000; 46: 667-672.
6. Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: Relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000; 150: 167-177.
7. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Int Med 1999; 246: 341-355.
8. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81: 13B-17B.
9. Tomono S, Kawazu S, Kato N, Ono T, Ishii C, Ito Y et al. Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J Atheroscl Thromb 1994; 1: 98-102.
10. Saniabadi AR, Umemura K, Shimoyama M, Adachi M, Nakano M, Nakashima Met al. Aggregation of human blood platelets by remnant-like lipoprotein particles of plasma chylomicrons and very low density lipoproteins. Thromb Heamost 1997; 77: 996-1001.
11. Doi H, Kugiyama K, Ohgushi M, Sugiyama S, Matsumura T, Ohta Y et al. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation. Atherosclerosis 1998; 137: 341-349.
12. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998; 97: 2519-2526.
13. Sakata K, Miho N, Shirotani M, Yoshida H, Takada Y, Takada A. Remnant-like particles cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary artery. Atherosclerosis 1998; 136: 225-231.
14. Karpe F, Hellenius ML, Hamsten A. Differences in postprandial concentrations of very low density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease. Metabolsim Clin Exp 1999; 48: 301-307.
15. Masuoka H, Kamei S, Wagayama H, Ozaki M, Kawasaki A, Tanaka T et al. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. Am Heart J 2000; 139: 305-310.
16. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol 2000; 11: 615-620.
17. Syvanne M, Vuorinen Markkola H, Hilden H, Taskinen MR. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1993; 13: 286-295.
18. Cavallero E, Piolot A, Jacotot B. Postprandial lipoprotein clearance in type 2 diabetes: Fenofibrate effects. Diabetes Metab 1995; 21: 118-120.
19. Reitsma JB, Cabezas MC, de Bruin TWA, Erkelens DW. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 1994; 43: 293-298.
20. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270-279.
21. Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J, Warnick GR et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 1998; 44: 2490-2498.
22. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992; 33: 369-380.
23. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM et al. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. Clin Chem 1998; 44: 1224-1232.
24. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99: 2858-2860.
25. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant proteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001; 42: 17-21.
26. Lewis GF, O'Meara NM, Soltys PA, Blackman JD, Iverius PH, Druetzler AF et al. Postprandial lipoprotein metabolism in normal and obese subjects: Comparison after the vitamin A fat-loading test. J Clin Endocrinol Metab 1990; 71: 1041-1050.
27. Lewis GF, O'Meara NM, Soltys PA, Blackman JD, Iverius PH, Pugh WL et al. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 1991; 72: 934-944.
28. Hogan S, Fleury A, Hadvary P, Lengsfeld H, Meier MK, Triscari J et al. Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int J Obes 1987; 11S3: 35-42.
29. Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Humphreys SM et al. Adipose tissue metabolism in obesity: Lipase action in vivo before and after a mixed meal. Metabolism 1992; 41: 264-272.
30. Cooper MB, Tan KCB, Hales CN, Betteridge DJ. Postprandial lipid metabolism and β-cell function in non-insulin-dependent (type 2) diabetes mellitus after a mixed meal with a high fat content. Diabet Med 1996; 13: 816-827.
31. Zhou YP, Grill V. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995; 80: 1584-1590.
32. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-138.
33. Grill V, Qvigstad E. Fatty acids and insulin secretion. Br J Nutr 2000; 83: S79-84.
34. Jeppesen J, Chen YD, Zhou MY, Wang T, Reaven GM. Effect of variations in oral fat and carbohydrate load on postprandial lipemia. Am J Clin Nutr 1995; 62: 1201-1205.
35. Murphy MC, Chapman C, Lovegrove JA, Isherwood SG, Morgan LM, Wright JW et al. Meal frequency; does it determine postprandial lipaemia? Eur J Clin Nutr 1996; 50: 491-497.
36. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-1294.